Ind-Swift Labs Q4 revenue rises to ₹1.7B, net profit at ₹151.1M

1 min read     Updated on 29 May 2026, 10:04 AM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Ind-Swift Laboratories Ltd. announced its Q4 FY26 results, reporting a revenue of ₹1.7 billion and a net profit of ₹151.1 million. The company achieved an EBITDA gain of ₹206 million, reversing a loss from the previous year. The board approved the audited financial results and re-appointed cost auditors for the upcoming fiscal year.

powered bylight_fuzz_icon
41006817

*this image is generated using AI for illustrative purposes only.

Ind-Swift Laboratories Ltd. has reported its consolidated financial results for the fourth quarter and financial year ended March 31, 2026. The company posted a revenue of ₹1.7 billion for the quarter, a year-on-year increase from ₹1.4 billion. Consolidated net profit stood at ₹151.1 million for the quarter ended March 31, 2026, compared to ₹2.22 billion in the prior-year period, which included an exceptional item of ₹2.16 billion.

Q4 Financial Highlights

The board of directors approved the audited financial results for the quarter and financial year ended March 31, 2026, at a meeting held on May 28, 2026. The company reported an EBITDA gain of ₹206 million for the quarter, a significant turnaround from a loss of ₹44 million in the same period last year, with an EBITDA margin of 12.12%. Profit before tax for the quarter was ₹171 million, compared to ₹146 million in the corresponding prior-year period.

The following table summarises the key consolidated financial metrics for the quarter:

Metric: Q4 Current Q4 Previous (YoY)
EBITDA: ₹206M (Gain) ₹44M (Loss)
EBITDA Margin: 12.12%
Revenue: ₹1.7B ₹1.4B
PBT: ₹171M ₹146M
Net Profit: ₹151.1M ₹2.22B*

*Prior-year net profit included an exceptional item of ₹2.16 billion.

Operational and Regulatory Updates

The statutory auditors, M/s. Rattan Kaur & Associates, issued an unmodified opinion on the standalone and consolidated financial results. The board also re-appointed M/s. V. Kumar & Associates, Cost Accountants, as the cost auditors for the financial year 2026-27. The company noted that the amalgamation of Ind Swift Limited with the company became effective from August 8, 2025, and the financial results reflect the combined entity post-amalgamation.

Ind-Swift Laboratories is a pharmaceutical entity with manufacturing facilities located in Punjab and Jammu & Kashmir, with its registered office situated in Chandigarh.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE915B01019/0caa51a7-79d3-4bc3-b39e-79445884f4f1.pdf

Historical Stock Returns for Ind Swift Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+3.65%+23.65%+52.44%+118.61%+83.89%+84.14%

How will the amalgamation with Ind Swift Limited influence revenue growth and operational efficiency in FY2027?

What strategies are in place to sustain the EBITDA margin of 12.12% in the coming quarters?

Are there any upcoming regulatory approvals or product launches expected to drive future revenue?

like15
dislike

Ind-Swift Laboratories Passes Four Special Resolutions via Postal Ballot, Approves Leadership Changes

3 min read     Updated on 06 May 2026, 03:52 AM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Ind-Swift Laboratories Limited passed four special resolutions via postal ballot, with the last date of receipt of postal ballot forms being April 30, 2026, covering leadership changes including the change in designation of Sh. N.R. Munjal, appointments of Sh. Himanshu Jain and Sh. Sahil Munjal as Managing Directors, and remuneration approval for Whole-Time Director Sh. Rishav Mehta. A total of 36,164,227 votes were polled, representing 41.6463% of outstanding shares, with all resolutions receiving over 99.87% votes in favour. The e-voting was conducted through CDSL from April 01, 2026 to April 30, 2026, with CS Vishal Arora serving as scrutinizer.

powered bylight_fuzz_icon
39565364

*this image is generated using AI for illustrative purposes only.

Ind-Swift Laboratories Limited has successfully passed four special resolutions through a postal ballot process, with the last date of receipt of postal ballot forms being April 30, 2026. The resolutions, disclosed to the stock exchanges on May 5, 2026, encompassed key leadership restructuring decisions, including the change in designation of a senior director, appointments of two Managing Directors, and approval of remuneration for the Whole-Time Director. All four resolutions were passed with the requisite majority via remote e-voting facilitated by Central Depository Services (India) Limited.

Resolutions Passed

The postal ballot covered four special resolutions, each receiving overwhelming shareholder approval. The following table summarises the resolutions put to vote:

Resolution No.: Type Description
Resolution 1 Special Change in designation of Sh. N.R. Munjal (DIN: 00015096)
Resolution 2 Special Appointment of Sh. Himanshu Jain (DIN: 00014533) as Managing Director (Domestic Operations)
Resolution 3 Special Appointment of Sh. Sahil Munjal (DIN: 00015407) as Managing Director (Global Operations)
Resolution 4 Special Payment of remuneration to Sh. Rishav Mehta (DIN: 03028663), Whole-Time Director

The promoter and promoter group were noted as not interested in any of the four agenda items.

Voting Results Summary

The remote e-voting platform was open from Wednesday, April 01, 2026 (9:00 A.M. IST) to Thursday, April 30, 2026 (5:00 P.M. IST). The record date for determining voting entitlements was Friday, March 27, 2026. As on the record date, the total number of shareholders stood at 39,222. A total of 36,164,227 votes were polled across all four resolutions, representing 41.6463% of the total outstanding shares of 86,836,558.

The detailed voting outcome for each resolution is presented below:

Metric: Resolution 1 Resolution 2 Resolution 3 Resolution 4
Votes in Favour 36,119,346 36,119,476 36,119,476 36,118,916
Votes Against 44,881 44,751 44,751 45,311
Total Votes Polled 36,164,227 36,164,227 36,164,227 36,164,227
% in Favour (of votes polled) 99.8759% 99.8763% 99.8763% 99.8747%
% Against (of votes polled) 0.1241% 0.1237% 0.1237% 0.1253%
Resolution Passed Yes Yes Yes Yes

Category-Wise Voting Breakdown

Across all four resolutions, the promoter and promoter group cast 32,210,187 votes via e-voting, representing 86.2751% of their total shareholding of 37,334,278 shares, with 100.0000% of their votes in favour. Public institutional shareholders polled 260,853 votes out of their total holding of 12,054,112 shares (2.1640%), with 83.0686% in favour and 16.9314% against across all resolutions. Public non-institutional shareholders polled 3,693,187 votes from a total holding of 37,448,168 shares (9.8621%), with votes in favour exceeding 99.96% across all resolutions.

Scrutinizer's Report and Process

The postal ballot notice was dated March 27, 2026, and the scrutinizer, CS Vishal Arora (Membership No. 4566, C.P. No. 3645), was appointed by the Board of Directors at its meeting held on March 27, 2026. The scrutinizer's report was issued to the company on May 5, 2026. The e-voting data was downloaded from the CDSL e-voting system in the presence of two independent witnesses, Ms. Anita Bhargav and Mr. Arun Kumar, who are not in the employment of the company. The scrutinizer confirmed that all four resolutions stand passed with the requisite majority under e-voting. The voting results and scrutinizer's report are available on the company's website at www.indswiftgroup.com . The disclosure was signed by Pardeep Verma, VP-Corporate Affairs & Company Secretary, and countersigned by Mr. Mavrattan Munjal, Chairman.

Historical Stock Returns for Ind Swift Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+3.65%+23.65%+52.44%+118.61%+83.89%+84.14%

How might the dual Managing Director structure, with Himanshu Jain overseeing domestic operations and Sahil Munjal leading global operations, impact Ind-Swift Laboratories' strategic expansion plans in international markets?

What does the relatively low institutional shareholder participation of 2.16% in the e-voting process suggest about institutional investor confidence in Ind-Swift Laboratories' governance and future direction?

How could the leadership restructuring, including N.R. Munjal's change in designation, influence Ind-Swift Laboratories' competitive positioning within India's pharmaceutical API and formulations sector?

like17
dislike

More News on Ind Swift Laboratories

1 Year Returns:+83.89%